Adlai Nortye (ANL) Competitors $2.11 +0.02 (+0.96%) Closing price 03:53 PM EasternExtended Trading$2.04 -0.07 (-3.32%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. AURA, ALMS, ARCT, AQST, SLDB, GLUE, TSHA, ESPR, TKNO, and ATAIShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Aura Biosciences (AURA), Alumis (ALMS), Arcturus Therapeutics (ARCT), Aquestive Therapeutics (AQST), Solid Biosciences (SLDB), Monte Rosa Therapeutics (GLUE), Taysha Gene Therapies (TSHA), Esperion Therapeutics (ESPR), Alpha Teknova (TKNO), and Atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Aura Biosciences Alumis Arcturus Therapeutics Aquestive Therapeutics Solid Biosciences Monte Rosa Therapeutics Taysha Gene Therapies Esperion Therapeutics Alpha Teknova Atai Life Sciences Adlai Nortye (NASDAQ:ANL) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, community ranking, dividends, valuation and earnings. Which has more volatility & risk, ANL or AURA? Adlai Nortye has a beta of -1.56, meaning that its share price is 256% less volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Do analysts prefer ANL or AURA? Adlai Nortye presently has a consensus target price of $9.00, suggesting a potential upside of 326.54%. Aura Biosciences has a consensus target price of $23.00, suggesting a potential upside of 302.80%. Given Adlai Nortye's higher probable upside, equities research analysts plainly believe Adlai Nortye is more favorable than Aura Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Does the media refer more to ANL or AURA? In the previous week, Aura Biosciences had 6 more articles in the media than Adlai Nortye. MarketBeat recorded 7 mentions for Aura Biosciences and 1 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Aura Biosciences' score of 0.78 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, ANL or AURA? Aura Biosciences has lower revenue, but higher earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M15.57-$104.87MN/AN/AAura BiosciencesN/AN/A-$76.41M-$1.75-3.26 Do institutionals & insiders have more ownership in ANL or AURA? 35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 5.4% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ANL or AURA more profitable? Adlai Nortye's return on equity of 0.00% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Aura Biosciences N/A -41.57%-36.43% Does the MarketBeat Community prefer ANL or AURA? Aura Biosciences received 18 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 65.00% of users gave Aura Biosciences an outperform vote. CompanyUnderperformOutperformAdlai NortyeOutperform Votes8100.00% Underperform VotesNo VotesAura BiosciencesOutperform Votes2665.00% Underperform Votes1435.00% SummaryAura Biosciences beats Adlai Nortye on 9 of the 15 factors compared between the two stocks. Remove Ads Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.86M$6.73B$5.54B$7.49BDividend YieldN/A2.79%5.35%4.04%P/E RatioN/A6.9923.2518.07Price / Sales15.57198.60361.2686.83Price / CashN/A65.6738.1634.64Price / BookN/A5.926.493.99Net Income-$104.87M$142.37M$3.21B$247.18M7 Day Performance-8.46%-9.32%-6.42%-6.42%1 Month Performance-8.26%-10.26%-0.68%-7.44%1 Year Performance-78.34%-15.08%6.05%-4.31% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye2.4346 of 5 stars$2.11+1.0%$9.00+326.5%-78.1%$77.86M$5M0.00127Gap UpAURAAura Biosciences2.2967 of 5 stars$5.86-7.6%$23.00+292.5%-19.7%$294.32MN/A-3.3950Gap DownALMSAlumis2.3252 of 5 stars$6.14+8.9%$26.00+323.5%N/A$289.94MN/A0.00N/AInsider TradeGap DownHigh Trading VolumeARCTArcturus Therapeutics2.5983 of 5 stars$10.59-8.5%$59.20+459.0%-68.3%$287.20M$138.39M-4.77180Gap DownAQSTAquestive Therapeutics1.4525 of 5 stars$2.90-4.0%$10.57+264.5%-26.6%$286.73M$57.56M-6.44160Analyst ForecastNews CoverageSLDBSolid Biosciences3.0772 of 5 stars$3.70-14.4%$15.67+323.4%-69.5%$286.72M$8.09M-1.22100Gap DownHigh Trading VolumeGLUEMonte Rosa Therapeutics3.0187 of 5 stars$4.64-9.0%$15.50+234.1%-35.1%$285.41M$75.62M-2.5490Short Interest ↓TSHATaysha Gene Therapies1.9337 of 5 stars$1.39-28.0%$6.63+376.6%-51.3%$284.95M$8.33M2.21180Gap DownHigh Trading VolumeESPREsperion Therapeutics3.7118 of 5 stars$1.44-4.0%$6.75+368.8%-51.7%$284.90M$332.31M-2.25200News CoverageGap DownTKNOAlpha Teknova1.188 of 5 stars$5.19-0.4%$8.50+63.8%+118.4%$277.34M$37.75M-7.01240Gap UpHigh Trading VolumeATAIAtai Life Sciences3.4565 of 5 stars$1.36-7.5%$9.00+561.8%-20.9%$269.70M$308,000.00-1.6880Gap Down Remove Ads Related Companies and Tools Related Companies Aura Biosciences Alternatives Alumis Alternatives Arcturus Therapeutics Alternatives Aquestive Therapeutics Alternatives Solid Biosciences Alternatives Monte Rosa Therapeutics Alternatives Taysha Gene Therapies Alternatives Esperion Therapeutics Alternatives Alpha Teknova Alternatives Atai Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANL Stock Free ANL Stock Alerts